The approval should help the big pharmaceutical fight off competition from other drugs in the same class.
News & Analysis: Eli Lilly and Company
These two big drugmakers are in very different positions right now. And one is the clear choice for long-term investors.
The health insurer hopes that making prescriptions affordable will keep the people it covers healthier, which should save it money in the long run.
Which of these top dividend growth stocks is the more attractive buy right now?
The drug moves closer to an expanded approval for the skin disorder.
Lilly and Roche reported their latest disappointments in attempting to effectively treat Alzheimer's by attacking amyloid plaques.
The market moved higher to start the week.
From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs it's reviewing this month.
Reyvow is the first drug in an entirely new class of acute migraine treatments.
LLY earnings call for the period ending December 31, 2019.